42. Chordoma and chondroid tumors of the skull base: A clinicopathological study

B. Pollo, L. Giannachi, C. L. Solero, S. Giombini

Research output: Contribution to journalArticle

Abstract

Cartilaginous tumors of the skull base are uncommon and their classification remains still debated. These neoplasms have a great tendency to local recur and are often fatal because their critical location and their progression with bone involvement, even if adjuvant radiotherapy is given after surgery. 31 patients with cartilaginous tumors of the cranial base who underwent surgery between 1984 and 1996 in our institute were studied: 17 with classical chordoma (mean age 50 y.), 10 with chondrosarcoma low-grade (mean age 37 y.), 3 mixed chondrosarcoma with chordoid elements (1) or chordoma with chondroid elements (2) ("true" chondroid chordoma) (mean age 41 y.) and 1 with dedifferentiated chordoma (sarcomatous) (age 65 y.). They were 18 females and 13 males, without predominance in different subtype. The mean age range of the patients was 46,6 years (range 11-71 years). The histological analysis was performed on Formalin or Carnoy fixed sections of the tumor specimens. To establish tumor subsets based upon immunophenotype, an immunohistochemical study was carried out with antibodies to cytokeratin, vimentin, S100, PCNA (Proliferating Cell Nuclear Antigen), and occasionally Epithelial Membrane Antigen (EMA). The morphology and the immunoreactivity, specifically for cytokeratins, allow to differentiate and to classify these tumors: chordomas are keratin immunopositive, chondrosarcomas immunonegative, and mixed tumors, with chordoid and chondroid elements, partially positive. The different subsets of cartilaginous tumors seems to be related to different prognosis. The chondrosarcoma had a better prognosis than chordoma, having longer survival: one patients was dead within 5 y. after treatment among the patients with chondrosarcoma, while 6 patients were dead in the same period after treatment in the patients with chordoma. In conclusion the study of the immunological staining pattern is critical to establish the histotype of cartilaginous tumors of the skull base and to separe distinct entity with a better prognosis.

Original languageEnglish
Pages (from-to)253
Number of pages1
JournalItalian Journal of Neurological Sciences
Volume18
Issue number4
Publication statusPublished - 1997

Fingerprint

Chordoma
Skull Base
Chondrosarcoma
Neoplasms
Keratins
Notochord
Mucin-1
Adjuvant Radiotherapy
Proliferating Cell Nuclear Antigen
Vimentin
Formaldehyde
Staining and Labeling
Bone and Bones

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

42. Chordoma and chondroid tumors of the skull base : A clinicopathological study. / Pollo, B.; Giannachi, L.; Solero, C. L.; Giombini, S.

In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 253.

Research output: Contribution to journalArticle

Pollo, B. ; Giannachi, L. ; Solero, C. L. ; Giombini, S. / 42. Chordoma and chondroid tumors of the skull base : A clinicopathological study. In: Italian Journal of Neurological Sciences. 1997 ; Vol. 18, No. 4. pp. 253.
@article{5a6a6f013b214b3c8d6ce57e14325ffa,
title = "42. Chordoma and chondroid tumors of the skull base: A clinicopathological study",
abstract = "Cartilaginous tumors of the skull base are uncommon and their classification remains still debated. These neoplasms have a great tendency to local recur and are often fatal because their critical location and their progression with bone involvement, even if adjuvant radiotherapy is given after surgery. 31 patients with cartilaginous tumors of the cranial base who underwent surgery between 1984 and 1996 in our institute were studied: 17 with classical chordoma (mean age 50 y.), 10 with chondrosarcoma low-grade (mean age 37 y.), 3 mixed chondrosarcoma with chordoid elements (1) or chordoma with chondroid elements (2) ({"}true{"} chondroid chordoma) (mean age 41 y.) and 1 with dedifferentiated chordoma (sarcomatous) (age 65 y.). They were 18 females and 13 males, without predominance in different subtype. The mean age range of the patients was 46,6 years (range 11-71 years). The histological analysis was performed on Formalin or Carnoy fixed sections of the tumor specimens. To establish tumor subsets based upon immunophenotype, an immunohistochemical study was carried out with antibodies to cytokeratin, vimentin, S100, PCNA (Proliferating Cell Nuclear Antigen), and occasionally Epithelial Membrane Antigen (EMA). The morphology and the immunoreactivity, specifically for cytokeratins, allow to differentiate and to classify these tumors: chordomas are keratin immunopositive, chondrosarcomas immunonegative, and mixed tumors, with chordoid and chondroid elements, partially positive. The different subsets of cartilaginous tumors seems to be related to different prognosis. The chondrosarcoma had a better prognosis than chordoma, having longer survival: one patients was dead within 5 y. after treatment among the patients with chondrosarcoma, while 6 patients were dead in the same period after treatment in the patients with chordoma. In conclusion the study of the immunological staining pattern is critical to establish the histotype of cartilaginous tumors of the skull base and to separe distinct entity with a better prognosis.",
author = "B. Pollo and L. Giannachi and Solero, {C. L.} and S. Giombini",
year = "1997",
language = "English",
volume = "18",
pages = "253",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - 42. Chordoma and chondroid tumors of the skull base

T2 - A clinicopathological study

AU - Pollo, B.

AU - Giannachi, L.

AU - Solero, C. L.

AU - Giombini, S.

PY - 1997

Y1 - 1997

N2 - Cartilaginous tumors of the skull base are uncommon and their classification remains still debated. These neoplasms have a great tendency to local recur and are often fatal because their critical location and their progression with bone involvement, even if adjuvant radiotherapy is given after surgery. 31 patients with cartilaginous tumors of the cranial base who underwent surgery between 1984 and 1996 in our institute were studied: 17 with classical chordoma (mean age 50 y.), 10 with chondrosarcoma low-grade (mean age 37 y.), 3 mixed chondrosarcoma with chordoid elements (1) or chordoma with chondroid elements (2) ("true" chondroid chordoma) (mean age 41 y.) and 1 with dedifferentiated chordoma (sarcomatous) (age 65 y.). They were 18 females and 13 males, without predominance in different subtype. The mean age range of the patients was 46,6 years (range 11-71 years). The histological analysis was performed on Formalin or Carnoy fixed sections of the tumor specimens. To establish tumor subsets based upon immunophenotype, an immunohistochemical study was carried out with antibodies to cytokeratin, vimentin, S100, PCNA (Proliferating Cell Nuclear Antigen), and occasionally Epithelial Membrane Antigen (EMA). The morphology and the immunoreactivity, specifically for cytokeratins, allow to differentiate and to classify these tumors: chordomas are keratin immunopositive, chondrosarcomas immunonegative, and mixed tumors, with chordoid and chondroid elements, partially positive. The different subsets of cartilaginous tumors seems to be related to different prognosis. The chondrosarcoma had a better prognosis than chordoma, having longer survival: one patients was dead within 5 y. after treatment among the patients with chondrosarcoma, while 6 patients were dead in the same period after treatment in the patients with chordoma. In conclusion the study of the immunological staining pattern is critical to establish the histotype of cartilaginous tumors of the skull base and to separe distinct entity with a better prognosis.

AB - Cartilaginous tumors of the skull base are uncommon and their classification remains still debated. These neoplasms have a great tendency to local recur and are often fatal because their critical location and their progression with bone involvement, even if adjuvant radiotherapy is given after surgery. 31 patients with cartilaginous tumors of the cranial base who underwent surgery between 1984 and 1996 in our institute were studied: 17 with classical chordoma (mean age 50 y.), 10 with chondrosarcoma low-grade (mean age 37 y.), 3 mixed chondrosarcoma with chordoid elements (1) or chordoma with chondroid elements (2) ("true" chondroid chordoma) (mean age 41 y.) and 1 with dedifferentiated chordoma (sarcomatous) (age 65 y.). They were 18 females and 13 males, without predominance in different subtype. The mean age range of the patients was 46,6 years (range 11-71 years). The histological analysis was performed on Formalin or Carnoy fixed sections of the tumor specimens. To establish tumor subsets based upon immunophenotype, an immunohistochemical study was carried out with antibodies to cytokeratin, vimentin, S100, PCNA (Proliferating Cell Nuclear Antigen), and occasionally Epithelial Membrane Antigen (EMA). The morphology and the immunoreactivity, specifically for cytokeratins, allow to differentiate and to classify these tumors: chordomas are keratin immunopositive, chondrosarcomas immunonegative, and mixed tumors, with chordoid and chondroid elements, partially positive. The different subsets of cartilaginous tumors seems to be related to different prognosis. The chondrosarcoma had a better prognosis than chordoma, having longer survival: one patients was dead within 5 y. after treatment among the patients with chondrosarcoma, while 6 patients were dead in the same period after treatment in the patients with chordoma. In conclusion the study of the immunological staining pattern is critical to establish the histotype of cartilaginous tumors of the skull base and to separe distinct entity with a better prognosis.

UR - http://www.scopus.com/inward/record.url?scp=33746365595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746365595&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746365595

VL - 18

SP - 253

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 4

ER -